We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.12B
AUM Growth
+$199M
Cap. Flow
+$144M
Cap. Flow %
12.84%
Top 10 Hldgs %
31%
Holding
95
New
1
Increased
36
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.1M
2
LLY icon
Eli Lilly
LLY
+$9.29M
3
MDT icon
Medtronic
MDT
+$9.04M
4
CI icon
Cigna
CI
+$7.04M
5
ELV icon
Elevance Health
ELV
+$6.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.59M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.42M
4
AIMT
Aimmune Therapeutics
AIMT
+$4.76M
5
OMCL icon
Omnicell
OMCL
+$4.24M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Communication Services 2.08%
3 Industrials 0.52%
4 Technology 0.02%
5 Energy 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$132B
$17.5M 1.55%
290,000
-90,000
-24% -$5.42M
BSX icon
27
Boston Scientific
BSX
$73.1B
$17.2M 1.53%
450,000
+40,000
+10% +$1.54M
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$16.9M 1.5%
455,000
+30,000
+7% +$1.19M
NKTR icon
29
Nektar Therapeutics
NKTR
$2.53B
$16.6M 1.48%
66,667
+14,000
+27% +$4.4M
XLRN
30
DELISTED
Acceleron Pharma
XLRN
$16.3M 1.45%
145,000
-10,000
-6% -$996K
MGNX icon
31
MacroGenics
MGNX
$259M
$16M 1.42%
635,711
-39,289
-6% -$1.07M
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
$15.8M 1.4%
210,778
– –
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$29B
$14.6M 1.29%
100,000
+37,905
+61% +$5.39M
CVS icon
34
CVS Health
CVS
$122B
$14M 1.25%
240,000
+13,000
+6% +$809K
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
$13.7M 1.22%
70,000
-5,000
-7% -$837K
MRK icon
36
Merck
MRK
$323B
$13.3M 1.18%
167,680
– –
TMO icon
37
Thermo Fisher Scientific
TMO
$222B
$13.2M 1.18%
30,000
+11,000
+58% +$4.54M
REGN icon
38
Regeneron Pharmaceuticals
REGN
$83.2B
$12.6M 1.12%
22,500
+10,000
+80% +$6.06M
BAX icon
39
Baxter International
BAX
$14.4B
$12.5M 1.11%
155,000
+60,000
+63% +$5.05M
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.2M 1.08%
475,000
– –
IOVA icon
41
Iovance Biotherapeutics
IOVA
$2.9B
$11.2M 1%
340,000
– –
ZBH icon
42
Zimmer Biomet
ZBH
$18.7B
$11.2M 0.99%
84,460
+25,750
+44% +$3.36M
XNCR icon
43
Xencor
XNCR
$1.6B
$10.1M 0.9%
260,000
– –
AERI
44
DELISTED
Aerie Pharmaceuticals
AERI
$10M 0.89%
850,000
+260,000
+44% +$3.17M
EW icon
45
Edwards Lifesciences
EW
$53B
$9.58M 0.85%
120,000
– –
LIVN icon
46
LivaNova
LIVN
$4.21B
$9.49M 0.84%
210,000
-10,000
-5% -$484K
SILK
47
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$9.41M 0.84%
140,000
– –
BIIB icon
48
Biogen
BIIB
$30.6B
$9.36M 0.83%
33,000
+16,000
+94% +$4.46M
HCA icon
49
HCA Healthcare
HCA
$89.6B
$9.35M 0.83%
75,000
– –
ISRG icon
50
Intuitive Surgical
ISRG
$139B
$8.51M 0.76%
36,000
-15,000
-29% -$3.37M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rhenman & Partners Asset Management held 95 positions worth $1.12B, up 22% from $926M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $144M of net new capital in Q3 2020, opening 1 new position and adding to 36 existing holdings. Its largest new stake was Accolade Inc: 151,674 shares worth $5.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Communication Services and Industrials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $12.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2020 buy was Accolade Inc: 151,674 shares worth $5.9M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $56.1M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $12.1M.
  • Rhenman & Partners Asset Management fully exited Aimmune Therapeutics in Q3 2020, selling an estimated $4.76M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.12B portfolio in Q3 2020.
  • Rhenman & Partners Asset Management opened 1 new position and closed 13 in Q3 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 22% quarter-over-quarter to $1.12B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.